Highlights Newsletter 2

This newsletter presents you the following key sessions:

1. PODCAST with dr. Srdan Verstovsek about long term exposure to momelotinib in JAK inhibitor naïve and
    previously JAK inhibitor treated intermediate or high risk myelofibrosis patients

2. Bosutinib for newly diagnosed chronic phase chronic myeloid leukaemia: final 5-year follow-up of the
    phase III BFORE trial

3. Dose-escalation of oral azacitidine provides clinical benefit to acute myeloid leukaemia patients in first
    remission post induction

4. Axicabtagene-ciloleucel: also an option for patients with relapsed/refractory indolent non-Hodgkin
    lymphoma?

5. Gene therapy with etranacogene dezaparvovec in moderate to severe haemophilia B with pre-existing
    anti-capsid neutralising antibodies